Table 3. Evolution of the cellular immune response to JC virus after HSCT.
| A. JCV-specific CD4+ T-cells | ||||
|---|---|---|---|---|
| Number of Subjects |
% IFN-γ+CD4+ T- cells (unadjusted mean ± std dev) |
Median (range) |
P (Kruskal- Wallis) |
|
|
Time from
transplant |
||||
| Pre Transplant | 23 | 0.55 ± 0.96 | 0 (0 – 5.44) | |
| 3 months | 15 | 0.89 ± 1.60 | 0.04 (0 – 7.83) | |
| 6 months | 20 | 1.01 ± 2.34 | 0 (0 – 13.43) | |
| 12 – 18 months | 23 | 2.91 ± 7.40 | 0.31 (0 – 44.12) | 0.0041 |
| Transplant type | ||||
| Cord | 6 | 1.02 ± 1.95 | 0 (0 – 8.21) | |
| MUD | 13 | 1.46 ± 3.28 | 0.03 (0 – 26.17) | |
| MRD | 11 | 1.48 ± 6.02 | 0.03 (0 – 44.12) | 0.54 |
| Conditioning | ||||
| MC | 22 | 1.00 ± 1.86 | 0.06 (0 – 9.32) | |
| RIC | 8 | 1.55 ± 4.90 | 0 (0 – 44.12) | 0.26 |
|
Graft versus host
disease |
||||
| No | 19 | 1.78 ± 5.13 | 0 (0 – 44.12) | |
| Yes | 11 | 0.88 ± 2.71 | 0.07 (0 – 26.17) | 0.76 |
|
Concurrent
viremia |
||||
| No | 19 | 1.57 ± 5.14 | 0.02 (0 – 44.12) | |
| Yes | 11 | 1.18 ± 2.83 | 0 (0 – 26.17) | 0.86 |
| Age | ||||
| <49 | 8 | 0.62 ± 1.14 | 0.01 (0 – 5.47) | |
| 49 – 58 | 8 | 2.48 ± 4.16 | 0.68 (0 – 26.17) | |
| 59 – 63 | 10 | 1.57 ± 6.20 | 0 (0 – 44.12) | |
| >63 | 4 | 0.53 ± 0.94 | 0 (0 – 3.84) | 0.0012 |
|
Diagnosis of
AML |
||||
| No | 17 | 1.61 ± 3.04 | 0.41 (0 – 26.17) | |
| Yes | 13 | 1.15 ± 5.43 | 0 (0 – 44.12) | <0.0001 |
| B. JCV-specific CD8+ T-cells | ||||
|---|---|---|---|---|
| Number of Subjects |
% IFN-γ+CD8+ T- cells (unadjusted mean ± std dev) |
Median (range) |
P (Kruskal- Wallis) |
|
|
Time from
transplant |
||||
| Pre Transplant | 23 | 0.16 ± 0.45 | 0 (0 – 3.26) | |
| 3 months | 15 | 0.06 ± 0.21 | 0 (0 – 1.40) | |
| 6 months | 20 | 0.25 ± 0.65 | 0 (0 – 4.32) | |
| 12 – 18 months | 23 | 1.12 ± 4.82 | 0 (0 – 33.96) | 0.11 |
| Transplant type | ||||
| Cord | 6 | 0.7 ± 3.14 | 0 (0 – 21.29) | |
| MUD | 13 | 0.54 ± 3.25 | 0 (0 – 33.96) | |
| MRD | 11 | 0.18 ± 0.57 | 0 (0 – 4.32) | 0.83 |
| Conditioning | ||||
| MC | 22 | 0.77 ± 3.41 | 0 (0 – 23.52) | |
| RIC | 8 | 0.31 ± 2.27 A | 0 (0 – 33.96) | 0.18 |
|
Graft versus host
disease |
||||
| No | 19 | 0.39 ± 2.56 | 0 (0 – 33.96) | |
| Yes | 11 | 0.50 ± 2.74 | 0 (0 – 23.52) | 0.90 |
|
Concurrent
viremia |
||||
| No | 19 | 0.52 ± 3.09 | 0 (0 – 33.96) | |
| Yes | 11 | 0.33 ± 1.86 | 0 (0 – 21.29) | 0.09 |
| Age | ||||
| <49 | 8 | 0.36 ± 2.11 | 0 (0 – 21.29) | |
| 49 – 58 | 8 | 1.13 ± 4.65 | 0 (0 – 33.96) | |
| 59 – 63 | 10 | 0.1 ± 0.28 | 0 (0 – 1.76) | |
| >63 | 4 | 0.08 ± 0.16 | 0 (0 – 0.67) | 0.08 |
|
Diagnosis of
AML |
||||
| No | 17 | 0.64 ± 3.18 | 0 (0 – 33.96) | |
| Yes | 13 | 0.2 ± 1.75 | 0 (0 – 21.29) | 0.003 |
HSCT: hematopoietic stem cell transplantation; Cord: umbilical cord blood transplantation; MUD: matched unrelated donor; MRD: matched related donor; MC: myeloablative conditioning; RIC: reduced intensity conditioning; AML: acute myelogenous leukemia.